Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids ADV SCI
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study Haematologica
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study BRIT J HAEMATOL
Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues Hum Genomics
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Mol Cancer Ther
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options Ann Hematol
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment CL LYMPH MYELOM LEUK
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study CL LYMPH MYELOM LEUK
Identification of novel NUP98 fusion partners and co-mutations in Acute Myeloid Leukemia: an adult cohort study Blood Adv